Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02992327 · ClinicalTrials.gov registry record
Biomarker Levels as A Predictor of Concussion Severity OUTcomes (BlacOut)
A clinical trial of Concussion, Mild and Neurocognitive Dysfunction, sponsored by HealthPartners Institute.
- Completed
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT02992327: Completed study of Concussion, Mild and Neurocognitive Dysfunction, sponsored by HealthPartners Institute.
NCT02992327 is a study of Concussion, Mild and Neurocognitive Dysfunction that has completed, run by HealthPartners Institute. The registered enrollment target is 100 participants, below the 198-participant average among 18 other Concussion, Mild trials with a reported enrollment target (49% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02992327, a study of Concussion, Mild and Neurocognitive Dysfunction, has completed, sponsored by HealthPartners Institute.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall research aim of this pilot study is to determine if the structural brain protein calpain-cleaved αII-spectrin N-terminal fragment (SNTF) can be used as a blood biomarker to accurately identify patients who will have more severe symptoms and reduced neurocognitive functioning after sustaining a concussion. Concussion is also referred to as mild traumatic brain injury (mTBI) in the literature. Both terms will be used interchangeably throughout this application.
Primary Outcome
Neurocognitive testing a 30 days post injury to assess symptom severity
Conditions Studied
Study Locations (1)
Minnesota
- Regions Hospital - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2015-08-30 |
| Est. Completion | 2018-08-06 |
What the finished NCT02992327 record still lists
NCT02992327 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 198-participant average among 18 other Concussion, Mild trials with a reported enrollment target (49% lower).
The record links to 2 conditions, with Concussion, Mild appearing as the primary indexed condition, and to 0 interventions.
NCT02992327 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT02992327 about?
NCT02992327 is a clinical study titled "Biomarker Levels as A Predictor of Concussion Severity OUTcomes (BlacOut)". The overall research aim of this pilot study is to determine if the structural brain protein calpain-cleaved αII-spectrin N-terminal fragment (SNTF) can be used as a blood biomarker to accurately identify patients who will have more severe symptoms and reduced neurocognitive functioning after sustai...
What is the current status of trial NCT02992327?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2015-08-30. Estimated completion is 2018-08-06.
What conditions does trial NCT02992327 study?
This clinical trial studies the following conditions: Concussion, Mild, Neurocognitive Dysfunction.
Who is sponsoring clinical trial NCT02992327?
This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02992327 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Concussion, Mild
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02992327's enrollment target sits among peer trials
100 10th of 18 higher than 8 of 18 other Concussion, Mild trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Concussion, Mild trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Acceptance and Commitment Therapy Integrated Vestibular Rehabilitation (ACTIVE) RCT
RECRUITING · NA
-
Eye Recovery Automation for Post Injury Dysfunction (iRAPID)
RECRUITING · NA
-
BCAAs in Concussion 2.0
RECRUITING · Phase 2
-
Facilitating Access to Specialty Treatment
RECRUITING · NA
-
Concussion Treatment in Older Adults
RECRUITING · NA
-
Poly-omic Predictors of Symptom Duration and Recovery for Adolescent Concussion
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI